Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Buy” from Brokerages

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given an average rating of “Buy” by the eight analysts that are currently covering the stock, MarketBeat reports. Seven research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $61.40.

A number of brokerages have issued reports on ARCT. HC Wainwright decreased their target price on shares of Arcturus Therapeutics from $63.00 to $60.00 and set a “buy” rating for the company in a research note on Friday. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating on the stock in a report on Friday. Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a report on Friday. Finally, BTIG Research started coverage on shares of Arcturus Therapeutics in a report on Tuesday, January 28th. They set a “buy” rating and a $41.00 price target on the stock.

Arcturus Therapeutics Stock Down 8.9 %

Shares of NASDAQ:ARCT opened at $14.55 on Monday. The firm has a fifty day moving average of $16.95 and a two-hundred day moving average of $18.55. The firm has a market capitalization of $394.12 million, a P/E ratio of -6.55 and a beta of 2.96. Arcturus Therapeutics has a 12-month low of $14.11 and a 12-month high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). The company had revenue of $22.77 million for the quarter, compared to analyst estimates of $44.64 million. Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. Equities research analysts expect that Arcturus Therapeutics will post -2.22 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Wellington Management Group LLP raised its holdings in Arcturus Therapeutics by 0.8% in the 4th quarter. Wellington Management Group LLP now owns 97,036 shares of the biotechnology company’s stock worth $1,647,000 after acquiring an additional 742 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in Arcturus Therapeutics by 10.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 8,694 shares of the biotechnology company’s stock worth $202,000 after acquiring an additional 846 shares during the period. Ameriprise Financial Inc. raised its holdings in Arcturus Therapeutics by 5.0% in the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company’s stock worth $316,000 after acquiring an additional 883 shares during the period. Virtus ETF Advisers LLC raised its holdings in Arcturus Therapeutics by 38.8% in the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after acquiring an additional 1,132 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its holdings in Arcturus Therapeutics by 7.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company’s stock worth $323,000 after acquiring an additional 1,279 shares during the period. Institutional investors own 94.54% of the company’s stock.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.